Core Insights - The Chinese healthcare industry experienced a significant surge in 2025, marked by a record number of innovative medical devices and drugs approved for market entry, indicating a growing focus on innovation in the sector [1][3] - The total value of overseas business development (BD) transactions for innovative drugs reached $135.7 billion in 2025, accounting for 49% of the global total, surpassing the United States for the first time [3] - The IPO market for healthcare companies in China saw a revival, with 37 companies successfully listed in 2025, doubling the number from 2024, reflecting strong investor interest in the sector [7] Innovation in Medical Devices and Drugs - In 2025, 109 innovative medical devices were approved, with a 19.67% year-on-year increase in Class III devices, while 76 innovative drugs were approved, focusing on advanced fields like oncology and autoimmune diseases [1] - The rapid growth in innovative drug approvals and medical device registrations highlights China's increasing capabilities in healthcare innovation [1][8] Business Development and Market Dynamics - The number of overseas BD transactions for innovative drugs reached 157 in 2025, with a total transaction value of $135.7 billion, both figures representing historical highs [3] - The increasing recognition of Chinese innovative drugs by global pharmaceutical companies is evident, particularly as they face pressures from patent expirations and global competition [8] IPO Activity and Market Sentiment - The healthcare sector in China saw a resurgence in IPO activity, with 37 companies going public in 2025, compared to 17 in 2024, indicating a robust market sentiment [7] - Over 60 healthcare companies are currently in the IPO pipeline on the Hong Kong Stock Exchange, reflecting sustained investor enthusiasm for the healthcare sector [7] Challenges and Industry Landscape - Despite the growth, challenges persist, including difficulties in financing and market entry for medical companies, exacerbated by domestic healthcare cost controls and intensified competition [7] - The industry is undergoing significant consolidation, presenting both opportunities and challenges for companies navigating this complex landscape [7][11] AI Integration in Healthcare - AI technology is increasingly integrated into the healthcare sector, enhancing the efficiency and safety of medical devices and drug development processes [10] - The shift towards data-driven, proactive healthcare solutions is transforming traditional practices, with AI expected to play a crucial role in future clinical pathways [10] Investment Trends and Future Outlook - The investment landscape in the healthcare sector is shifting towards high-tech, innovative companies, with a notable decrease in the number of financing events but an increase in total investment amounts [16] - The next 5-10 years are anticipated to be a golden period for innovation in Chinese healthcare, with a focus on projects that address unmet clinical needs [17]

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% over the next 6 months [14]. Core Insights - A breakthrough in Alzheimer's treatment was observed when a focused ultrasound surgery unexpectedly improved the cognitive function of a patient, challenging the traditional belief that Alzheimer's is irreversible. This condition affects nearly 17 million patients in China, leading to significant caregiving burdens [4][5]. - The research team led by Professor Sun Bomin is exploring a new approach using high-energy ultrasound to directly stimulate brain neural circuits, with initial clinical trials showing an average improvement rate of about 50% among seven moderate to severe patients [5]. - The global brain-computer interface (BCI) market is projected to grow rapidly, with an estimated size of approximately $2.62 billion in 2024, reaching $2.94 billion in 2025, and potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate of 17.35% over the next decade [6]. Summary by Sections Industry Overview - The report highlights the significant unmet medical need in Alzheimer's treatment and the potential for innovative therapies to emerge from recent clinical findings [4][5]. Market Potential - The brain-computer interface market is expected to see substantial growth, with specific projections for both global and Chinese markets, indicating a strategic focus on high-tech industries as outlined in national economic plans [6]. Investment Recommendations - The report suggests monitoring companies such as Yanshan Technology, Hanwei Technology, Sanbo Brain Science, and others, which are positioned to benefit from advancements in the BCI and related technologies [6].

最新公告列表 《关于诉讼事项的进展公告（三）》 截至2026年1月23日收盘，创新医疗（002173）报收于29.88元，较前一交易日上涨3.28%，最新总市值 为131.86亿元。该股当日开盘30.0元，最高30.45元，最低28.75元，成交额达23.03亿元，换手率为 18.59%。 近日，创新医疗管理股份有限公司披露《关于诉讼事项的进展公告（三）》。公告显示，公司于近日收 到上海金融法院就韩猛起诉公司及公司时任董事一案作出的终审判决，案号为（2025）沪74民终1586 号。法院判决驳回上诉，维持原判。二审案件受理费193,877元，由韩猛负担9,672元，公司负担184,205 元。该判决为终审判决。公司表示，本案对公司本期利润或期后利润无重大影响。截至公告日，公司及 控股子公司不存在应披露而未披露的其他重大诉讼、仲裁事项。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

证券代码：002173 证券简称：创新医疗 公告编号：2026-004 驳回上诉，维持原判。 二审案件受理费 193,877 元，由上诉人韩猛负担 9,672 元，上诉人创新医疗 管理股份有限公司负担 184,205 元。 本判决为终审判决。 二、上述案件对公司本期利润或期后利润的可能影响 创新医疗管理股份有限公司 关于诉讼事项的进展公告（三） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年9月，上海市浦东新区人民法院对韩猛以公司未办理相关股份的解除 限售手续为由，起诉公司及公司时任董事的相关案件作出一审判决。其后，公司 和韩猛均不服上述一审判决，向上海金融法院提起上诉，具体情况详见2025年11 月28日公司披露于《证券时报》、《证券日报》、《中国证券报》、《上海证券 报》以及巨潮资讯网(http://www.cninfo.com.cn)的相关公告（公告编号： 2025-054）。近日，公司收到上海金融法院关于上述案件的《民事判决书》（（2025） 沪74民终1586号）。现将有关情况公告如下： 一、本次收到《民事判决书》判决情况 公司于近日收到 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

剩余财产分配完毕后，本基金管理人将按照法律法规及相关规定办理本基金的账户注销等业务。投资人 可拨打本基金管理人的客户服务电话（400-700-8880）了解相关事宜。 华商基金管理有限公司 本基金自2025年12月20日至2025年12月29日期间进行了基金财产清算，基金财产清算报告报中国证监会 备案后，本基金管理人于2026年1月20日在本基金管理人网站（www.hsfund.com）和中国证监会基金电 子披露网站（http://eid.csrc.gov.cn/fund）刊登了《华商创新医疗混合型证券投资基金清算报告》（以下 简称"《清算报告》"）。根据《基金合同》的约定，《基金合同》终止日是指《基金合同》规定的《基 金合同》终止事由出现后，基金财产清算完毕，清算结果报中国证监会备案并予以公告的日期。据此， 本基金《基金合同》终止日为2026年1月20日。 根据《中华人民共和国证券投资基金法》《公开募集证券投资基金运作管理办法》《华商创新医疗混合 型证券投资基金基金合同（更新）》（以下简称"《基金合同》"）的有关规定，华商创新医疗混合型证 券投资基金（以下简称"本基金"）已出现触发《基金合同》终止的情形，华 ...

1月21日的资金流向数据方面，主力资金净流入3845.08万元，占总成交额3.3%，游资资金净流入 4050.81万元，占总成交额3.48%，散户资金净流出7895.88万元，占总成交额6.78%。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-21 | 28.37 | -0.14% | 3845.08万 | 3.30% | 4050.81万 | 3.48% | -7895.88万 | -6.78% | | 2026-01-20 | 28.41 | -3.20% | -9828.11万 | -7.33% | -4303.63万 | -3.21% | 1.41亿 | 10.54% | | 2026-01-19 | 29.35 | 0.51% | -9841.20万 | -6.09% | -2407.44万 | -1.49% | 1.22亿 | 7.58% | | 2026-01-16 | 29.20 | - ...

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - Xianjian Technology (01302) saw a significant increase in stock price, rising by 4.07% to HKD 1.79, with a trading volume of HKD 37.76 million following the approval of its innovative medical device by the National Medical Products Administration [1] Group 1: Product Approval - The Concave Supra integrated three-branch reconstruction system, co-developed by Professor Shu Chang from the National Center for Cardiovascular Diseases and Xianjian Technology, has been approved for entry into the special review process for innovative medical devices, known as the "green channel" for national innovation [1] - This marks the 17th product from Xianjian Technology to be approved for the national innovation "green channel," highlighting the company's commitment to research and development in the medical device sector [1] Group 2: Product Features - The CS stent system is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing a global first in providing a solution for integrated three-branch reconstruction without brain ischemia [1] - The product will complement Xianjian's existing innovative product matrix for aortic arch branch reconstruction, including chimney technology and in-situ fenestration techniques, thereby offering a comprehensive solution for endovascular treatment of aortic arch lesions [1]